New hope for esophageal cancer patients who failed immunotherapy
NCT ID NCT07524374
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, SHR-1701 and liposomal irinotecan, in 33 adults with esophageal squamous cell carcinoma who have already received immunotherapy. The goal is to see if the combo can shrink tumors or stop them from growing. Participants will receive the treatment and be monitored for side effects and disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
- New drug duo aims to wipe out esophageal tumors before surgery
- Could a drug combo let some esophageal cancer patients skip surgery?
- New drug cocktail shows promise against tough esophageal cancer
- New triple therapy hopes to outsmart tough esophageal cancer
- Could a new staging system better predict esophageal cancer outcomes?